Predicting Nerve Damage Induced by Chemotherapy

Not Applicable

Completed

• Conditions: Chemotherapy-induced neurotoxicity in cancer patients; Cancer - Any cancer

• Registration Number: ACTRN12612000029897
• Lead Sponsor: niversity of Auckland

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-01-09
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

Written informed consent Inclusion criteria
All adult male or female patients with cancer of any type presenting for standard chemotherapy that includes cisplatin, oxaliplatin or paclitaxel are candidates for study participation.

Exclusion Criteria

Exclusion criteria
Unable for give informed consent
Expected survival less than 6 months
Age less than 18 years

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
patient neurotoxicity outcomes after treatment with cisplatin, oxaliplatin and paclitaxel chemotherapy, for correlation with biological variables measured in blood samples[Blood specimens will be collected prior to treatment, prior to cycle 2, at end of treatment and 3 months after treatment.];Change in Total Neuropathy Score (Clinical)[from baseline to 3 months after treatment]

Secondary Outcome Measures

Name	Time	Method
Change on audiogram parameters measured by the severity grade for hearing toxicity[from baseline to 3 months after cisplatin treatment];occurrence of treatment-limiting neurotoxicity measured by changes in the neurotoxicity quality of life score questionnaire[from baseline to 3 months after treatment]